Chiasma Inc

Chiasma — Merger or Acquisition (May 2021)

23 slides from Chiasma's merger presentation, May 5, 2021

  1. Slide 1: Amryt Pharma acquisition of Chiasma Inc

    Amryt pharma acquisition of chiasma inc May 2021 Filed by: Chiasma, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Chiasma, Inc. Commission File No: 001-37500

  2. Slide 2: Disclaimer

    DisclaimeR This presentation has been prepared by the Company. “Presentation” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed during the meeting. By receiving this presentation and/or attending the meeting where th

  3. Slide 3: Forward-looking statements

    This press release may contain forward-looking statements containing the words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this

  4. Slide 4: Additional Information

    ADDITIONAL INFORMATION No Offer or Solicitation This communication is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdicti

  5. Slide 5: Amryt acquisition of Chiasma - Transaction Benefits

    Amryt acquisition of chiasma - Transaction BENEFITS Strengthens Amryt’s global leadership in developing and commercializing transformative therapies for rare & orphan diseases Combined business will have three approved commercial products lomitapide (Lojuxta®/Juxtapid®), metreleptin (Myalept®/ Myale

  6. Slide 6: Transaction Benefits contd.

    Transaction BENEFITS contd. a global leader in rare & orphan diseases Lead pipeline candidate Oleogel-S10*(Filsuvez®) under regulatory review in US and EU Acquisition leverages Amryt’s proven commercial execution ability expertise, global infrastructure and integration capabilities to accelerate MYC

  7. Slide 7: Combined Commercial Products

    Combined Commercial Products 2 marketed products with multiple lifecycle extension opportunities 1 marketed product in first full year of launch 3 marketed products with strong IP protection Infrastructure Global medical + commercial US medical + commercial Enhanced US plus global medical + commerci

  8. Slide 8: Amryt Corporate Overview

    AMRYT CORPORATE OVERVIEW GLOBAL, COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEDICATED TO ACQUIRING, DEVELOPING AND COMMERCIALIZING NOVEL TREATMENTS FOR RARE DISEASES EBITDA positive and growing commercial business with two commercial products (metreleptin and lomitapide) and a significant developmen

  9. Slide 9: Consistent Performance and Growth

    CONSISTENT PERFORMANCE AND GROWTH * Unaudited combined revenues for 2019 represent the pro forma combined unaudited revenues of the Company assuming the acquisition by Amryt of Aegerion happened on 1 January 2019. These amounts (i) exclude revenues from sales to end-users in Japan, due to the out-li

  10. Slide 10: Metreleptin - Lipodystrophy Market Overview

    Metreleptin - LIPODYSTROPHY Market Overview The global market LD market is estimated at $530 million with US estimated at ~$280 million Fatty liver Insatiable appetite Chronic fatigue Diabetes Pancreatitis Organ damage Reduced life expectancy Lipodystrophy is a chronic condition associated with low

  11. Slide 11: Lomitapide - HoFH Market Overview

    LOMITAPIDE - HoFH Market Overview Lomitapide is approved as an adjunct to a low-fat diet and other lipid-lowering medicinal treatments for adults with the rare cholesterol disorder, Homozygous Familial Hypercholesterolaemia ("HoFH") in the US, Canada, Columbia, Argentina and Japan (under the trade n

  12. Slide 12: Oleogel-S10: Potential first in market therapy for epidermolysis bullosa

    Oleogel-s10: Potential first in market therapy for epidermolysis bullosa Regulatory submissions filed with FDA and EMA. If approved, US launch anticipated Q4 2021 EU anticipated Q2 2022 Received Fast Track Designation Granted Rare Pediatric Disease Designation by FDA The global market is estimated t

  13. Slide 13: Growing Commercial Portfolio & Enhanced Combined Development Pipeline

    GROWING COMMERCIAL PORTFOLIO & ENHANCED COMBINED Development Pipeline EARLY AND LATE-STAGE PIPELINE WITH MULTIPLE VALUE INFECTION POINTS Definitions: Dystrophic EB (“DEB”); Junctional EB (‘‘JEB’’); Recessive Dystrophic EB (‘‘RDEB’’) * Upcoming clinical milestones are subject to the impact of COVID-1

  14. Slide 14: Global Infrastructure

    GLOBAL INFRASTRUCTURE INFRASTRUCTURE IN PLACE TO DRIVE GLOBAL GROWTH 7 Current markets Pending markets Out-licensed BA Pharma Trading Ltd

  15. Slide 15: Chiasma Overview

    CHIASMA Overview MYCAPSSA® was approved by FDA in June 2020 and launched in September 2020 as the first and only oral (SSA) for patients with acromegaly Significant market potential for MYCAPSSA® in NET Patent protection for MYCAPSSA® in the US and EU to 2029 with method of use coverage in US to 203

  16. Slide 16: MYCAPSSA - Acromegaly - US Market Overview

    MycapSsa® - Acromegaly - US Market Overview Octreotide and lanreotide injections are broadly used as first-line pharmacological treatments Injections Present Significant Challenges to Patients** The global market for SSAs in the treatment of acromegaly is estimated at ~$800 million with US estimated

  17. Slide 17: Strategic Intent: make MYCAPSSA the new standard of care

    STRATEGIC Intent: to make MYCAPSSA® the NEW pharmacological standard of care Patients2 Over 185M Lives Covered3 Compelling Value for Payers Positive Patient Feedback Oral Option addresses unmet need SSAs already reimbursed and in payers' budgets MYCAPSSA® pricing designed to facilitate broad access

  18. Slide 18: Global SSA Sales expected to be ~$3.8B by 2028

    Global SSA Sales expected to be ~$3.8B by 2028 $2.3B $2.8B $2.6B $3.8B $0.8B $1.9B $0.1B $1.1B $2.4B $0.3B Financial reports & filings, Novartis & Ipsen, 2016–2019 Future projected growth at 3.5% to 2028 55% of global sales in US market (Novartis Annual Report for sales in 2019) Other

  19. Slide 19: Neuroendocrine Tumor (NET) - Market Overview

    Neuroendocrine Tumor (NET) - Market Overview Octreotide LAR and lanreotide depot injections are broadly used as first-line pharmacological treatments Potential addressable patient population on SSAs estimated at ~24,000 in the US2 NET Symptoms Include: GI Tract Malignancies Diarrhea & Constipation P

  20. Slide 20: TPE - Validated delivery technology platform

    TPE - Validated delivery technology platform Capsules with TPE technology have an enteric coating to protect against degradation in the stomach. Once in the small intestine, the capsule is designed to dissolve and release the TPE formulation. TPE technology induces the reversible expansion of tight

  21. Slide 21: Chiasma - Rationale for the combination

    CHIASMA – Rationale for the combination The combination with AMRYT is expected to: Consistent with our vision of becoming a successful commercial company with a promising pipeline. Capitalize on Amryt’s financial strength to expand the potential benefits of MYCAPSSA® in NET and other new development

  22. Slide 22: Combination delivers long term value to patients and shareholders

    COMBINATION DELIVERS LONG TERM VALUE TO PATIENTS AND SHAREHOLDERS Leading global commercial-stage orphan disease company with three growing marketed products in large attractive markets with active development / life cycle opportunities to expand to new indications Combination represents a compellin

  23. Slide 23: Questions & Answers

    Answers Questions &

Chiasma — Merger or Acquisition (May 2021) on 6ix